These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India. Singh N; Chatterjee M; Sundar S Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494 [TBL] [Abstract][Full Text] [Related]
24. Varicella zoster virus meningitis complicating sodium stibogluconate treatment for cutaneous leishmaniasis. Hartzell JD; Aronson NE; Nagaraja S; Whitman T; Hawkes CA; Wortmann G Am J Trop Med Hyg; 2006 Apr; 74(4):591-2. PubMed ID: 16606989 [TBL] [Abstract][Full Text] [Related]
25. Sodium stibogluconate cardiotoxicity and safety of generics. Rijal S; Chappuis F; Singh R; Boelaert M; Loutan L; Koirala S Trans R Soc Trop Med Hyg; 2003; 97(5):597-8. PubMed ID: 15307436 [TBL] [Abstract][Full Text] [Related]
26. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Gasser RA; Magill AJ; Oster CN; Franke ED; Grögl M; Berman JD Clin Infect Dis; 1994 Jan; 18(1):83-90. PubMed ID: 7519887 [TBL] [Abstract][Full Text] [Related]
27. Emergence of visceral leishmaniasis in Sri Lanka: a newly established health threat. Siriwardana HVYD; Karunanayake P; Goonerathne L; Karunaweera ND Pathog Glob Health; 2017 Sep; 111(6):317-326. PubMed ID: 28820339 [TBL] [Abstract][Full Text] [Related]
28. Pancreatitis and palindromic arthropathy with effusions associated with sodium stibogluconate treatment in a renal transplant recipient. Donovan KL; White AD; Cooke DA; Fisher DJ J Infect; 1990 Jul; 21(1):107-10. PubMed ID: 2166765 [TBL] [Abstract][Full Text] [Related]
29. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033 [TBL] [Abstract][Full Text] [Related]
30. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis. Elshafie AI; Ahlin E; Mathsson L; ElGhazali G; Rönnelid J J Immunol; 2007 Apr; 178(8):5383-9. PubMed ID: 17404324 [TBL] [Abstract][Full Text] [Related]
31. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani. Sinha R; Roychoudhury J; Palit P; Ali N Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907 [TBL] [Abstract][Full Text] [Related]
32. Conduction defect following pentavalent antimony therapy in visceral leishmaniasis. Ahasan HA; Chowdhury MA; Azhar MA; Rafiqueuddin AK; Islam F Trop Doct; 1997 Jan; 27(1):59-61. PubMed ID: 9030031 [No Abstract] [Full Text] [Related]
33. Visceral leishmaniasis in a renal transplant recipient: diagnostic and therapeutic problems. Sharma RK; Jha R; Kumar P; Kher V; Gupta A; Kumar A; Gulati S; Arora P; Murari M; Bhandari M Am J Nephrol; 1996; 16(4):358-60. PubMed ID: 8739293 [TBL] [Abstract][Full Text] [Related]
34. [A case of antimony resistant kala-azar cured with amphotericin B]. Chen SB; Yang CM; Zhang CJ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767 [No Abstract] [Full Text] [Related]
35. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Bryceson AD; Chulay JD; Mugambi M; Were JB; Gachihi G; Chunge CN; Muigai R; Bhatt SM; Ho M; Spencer HC Trans R Soc Trop Med Hyg; 1985; 79(5):705-14. PubMed ID: 3006295 [TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani. Ranawaka RR; Weerakoon HS J Dermatolog Treat; 2010 Sep; 21(5):286-93. PubMed ID: 20438389 [TBL] [Abstract][Full Text] [Related]
37. Studies on stibanate resistant Leishmania donovani isolates of Indian origin. Pal S; Mandal A; Duttagupta S Indian J Exp Biol; 2001 Mar; 39(3):249-54. PubMed ID: 11495284 [TBL] [Abstract][Full Text] [Related]
38. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates. Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301 [TBL] [Abstract][Full Text] [Related]
39. Problems in the treatment of kala-azar: case report. Nyakundi PM; Rashid JR; Wasunna KM; Were JB; Muigai R; Kirigi G; Mbugua J East Afr Med J; 1995 Jun; 72(6):406-8. PubMed ID: 7498017 [TBL] [Abstract][Full Text] [Related]
40. Electron microscopy of Leishmania donovani in splenic aspirates from patients with visceral leishmaniasis during treatment with sodium stibogluconate. Chulay JD; Fawcett DW; Chunge CN Ann Trop Med Parasitol; 1985 Aug; 79(4):417-29. PubMed ID: 3000304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]